

Financial news for OMED dated on 2019-04-23: UPDATE: Mereo BioPharma Confirmed Purchase Of OncoMed Pharma As Of Apr. 18, 2019

Financial news for OMED dated on 2019-04-23: OncoMed Pharma Shares Halted For Info Requested By Nasdaq

Financial news for OMED dated on 2019-04-18: The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio

Financial news for OMED dated on 2019-04-18: Mereo BioPharma Group Confirms Acquisition of OncoMed Pharmaceuticals Following Approval by OncoMed Stockholders

Financial news for OMED dated on 2019-04-17: OncoMed Pharmaceuticals shares are trading higher after the company received approval for its merger with Mereo.

Financial news for OMED dated on 2019-04-17: SEC Documents Show Approval Of Co.'s Merger Agreement With Mereo BioPharma Group

Financial news for OMED dated on 2019-03-15: OncoMed Pharma Declares Special Dividend 'in the form of a contractual right to receive, on a pro rata basis, cash payments from OncoMed upon the actual receipt by OncoMed of certain contingent cash amounts in the future following the exercise by Celgene'

Financial news for OMED dated on 2019-03-07: OncoMed Pharmaceuticals Q4 EPS \$(0.12) Beats \$(0.22) Estimate, Sales \$10.18M Beat \$9.01M Estimate

Financial news for OMED dated on 2018-12-21: When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?

Financial news for OMED dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for OMED dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for OMED dated on 2018-12-17: 4 Stocks Moving In Monday's After-Hours Session

Financial news for OMED dated on 2018-12-17: OncoMed Pharmaceuticals shares trading up after Mereo BioPharma reported a 10.7% stake in the company.

Financial news for OMED dated on 2018-12-17: OncoMed Pharmaceuticals 13D Shows Mereo BioPharma Group Holds 10.7% Stake In Co.

Financial news for OMED dated on 2018-12-14: IPOs, M&A, and Dividends: Taking A Look At Year-End News Catalysts

Financial news for OMED dated on 2018-12-14: Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018

Financial news for OMED dated on 2018-12-14: The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

Financial news for OMED dated on 2018-12-13: The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

Financial news for OMED dated on 2018-12-07: The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

Financial news for OMED dated on 2018-12-06: Mereo BioPharma And OncoMed Pharmaceuticals On Wednesday Announced Proposed Business Combination

Financial news for OMED dated on 2018-12-06: Benzinga's Top Upgrades, Downgrades For December 6, 2018

Financial news for OMED dated on 2018-12-06: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering

Financial news for OMED dated on 2018-12-06: Wells Fargo Downgrades OncoMed Pharmaceuticals to Market Perform, Announces \$1.50 Price Target

Financial news for OMED dated on 2018-12-04: Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018

Financial news for OMED dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for OMED dated on 2018-11-29: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018

Financial news for OMED dated on 2018-11-29: The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved

Financial news for OMED dated on 2018-11-21: OncoMed Shares Spike To Session High, Up 4%; Traders Circulate Specification Doc From European Patent Office For Method For Making Heteromultimeric Molecules

Financial news for OMED dated on 2018-11-16: The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal

Financial news for OMED dated on 2018-11-15: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018

Financial news for OMED dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for OMED dated on 2018-11-09: OncoMed Reports Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage Solid Tumors

Financial news for OMED dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for OMED dated on 2018-11-01: OncoMed Pharmaceuticals Q3 EPS \$0.16 Beats \$(0.20) Estimate, Sales \$19.5M Beat \$7.38M Estimate

Financial news for OMED dated on 2018-10-22: OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer

Financial news for OMED dated on 2018-10-20: OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer Show Overall Clinical Benefit Rate of 85% at ESMO 2018

Financial news for OMED dated on 2018-10-18: 41 Stocks Moving In Thursday's Mid-Day Session

Financial news for OMED dated on 2018-10-18: 46 Biggest Movers From Yesterday

Financial news for OMED dated on 2018-10-17: OncoMed 8-K Shows On Oct. 15, Celgene Notified Co. Of Decision Not To Exercise Option To License Rosmantuzumab; OncoMed Will Retain Worldwide Rights To Rosmantuzumab Upon Termination Of Collaboration Deal With Celgene

Financial news for OMED dated on 2018-10-17: OncoMed shares are up following the release of an abstract highlighting a Phase 1b study of navicixizumab and paclitaxel in ovarian cancer.

Financial news for OMED dated on 2018-10-17: Hearing OncoMed Pharmaceuticals Just Posted Abstract For ESMO For Saturday; Abstract Shows Navicixizumab & Weekly Paclitaxel In Ovarian Cancer Showed 44% Response Rate, vs 25% In Prior Trial

Financial news for OMED dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for OMED dated on 2018-10-04: 55 Biggest Movers From Yesterday

Financial news for OMED dated on 2018-09-24: OncoMed Announces 19 of 66 Patients in its Phase 1a Trial of Navicixizumab Showed Tumor Shrinkage

Financial news for OMED dated on 2018-09-21: 56 Biggest Movers From Yesterday

Financial news for OMED dated on 2018-09-20: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for OMED dated on 2018-09-20: OncoMed Pharma Offers Update On Navicixizumab Partnership: Celgene Notified Co. It Will Not Exercise Option To License Co.'s Navicixizumab; Celgene Cited 'strategic product portfolio considerations'

Financial news for OMED dated on 2018-08-27: 44 Biggest Movers From Friday

Financial news for OMED dated on 2018-08-02: OncoMed Pharmaceuticals Q2 EPS \$(0.10) Beats \$(0.23) Estimate, Sales \$6.87M Miss \$7.06M Estimate

Financial news for OMED dated on 2018-06-12: OncoMed Reports Dosing Of First Patient In Phase 1b Portion Of Anti-TIGIT Trial

Financial news for OMED dated on 2018-05-08: OncoMed Pharmaceuticals Q1 EPS \$(0.15) Beats \$(0.22) Estimate, Sales \$7.84M Beat \$6.41M Estimate

Financial news for OMED dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for OMED dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for OMED dated on 2018-03-27: 41 Biggest Movers From Yesterday

Financial news for OMED dated on 2018-03-19: OncoMed Names Dr. John Lewicki CEO

Financial news for OMED dated on 2018-03-12: 44 Biggest Movers From Friday

Financial news for OMED dated on 2018-03-09: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for OMED dated on 2018-03-08: OncoMed Reports Q4 EPS \$0.25 vs \$(0.60) In Same Qtr. Last Year, Sales \$20.64M vs \$6.22M YoY

Financial news for OMED dated on 2018-03-08: OncoMed Pharmaceuticals Q4 Earnings Preview

Financial news for OMED dated on 2018-03-07: 44 Biggest Movers From Yesterday

Financial news for OMED dated on 2018-03-01: Adam Feuerstein Tweets: \$OMER -- the only sell-side question came from Steve Brozak, who embarrassed himself as always. Ugly.

Financial news for OMED dated on 2018-01-04: OncoMed Sees FY18 Operating Cash Burn Less Than \$55M

Financial news for OMED dated on 2018-01-04: UPDATE: OncoMed Says FY17 Cash Burn ~\$81.5M

Financial news for OMED dated on 2018-01-04: UPDATE: OncoMed CFO Patel To Serve As Interim CEO, Perry Karsen Appointed Board Chairman

Financial news for OMED dated on 2018-01-04: OncoMed Sees 'Presentation of Clinical Data on Phase 1 programs expected in 2018'

Financial news for OMED dated on 2018-01-04: OncoMed Reports Yearend '17 Cash Balance \$103.1M

Financial news for OMED dated on 2018-01-04: OncoMed Announces CEO Hastings Has Resigned

Financial news for OMED dated on 2017-12-13: 40 Biggest Movers From Yesterday

Financial news for OMED dated on 2017-11-27: OncoMed Says CEO Paul Hastings To Resume Board Chairman Responsibilities

Financial news for OMED dated on 2017-11-02: OncoMed Pharmaceuticals Reports Q3 EPS \$(0.28) vs \$(0.41) Est., Sales \$5.1M vs \$5.12M Est.

Financial news for OMED dated on 2017-09-19: OncoMed Pharmaceuticals CEO Paul Hastings Takes Leave Of Absence For Medical Reasons

Financial news for OMED dated on 2017-09-13: OncoMed Doses First Patient with GITRL-Fc for Phase 1a Clinical Trial

Financial news for OMED dated on 2017-08-02: OncoMed Pharma Reports Q2 EPS \$(0.40) vs \$(0.50) Est., Sales \$6.2M vs \$4.85M Est.

Financial news for OMED dated on 2017-07-10: 8-K From OncoMed Shows Co. Received Letter From GlaxoSmithKline Indicating Co. Terminated R&D Collaboration, Option, License Deal

Financial news for OMED dated on 2017-06-06: PrimeCap Management Reports 14.63% Stake In Oncomed Pharmaceuticals

Financial news for OMED dated on 2017-05-24: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for OMED dated on 2017-05-24: Oncomed +21.5% Premarket @\$4.40

Financial news for OMED dated on 2017-05-08: 20 Stocks Moving In Monday's Pre-Market

Session

Financial news for OMED dated on 2017-05-08: OncoMed Q1 EPS \$(0.61) vs \$(0.63) Est, Sales \$6.21M vs \$6.97M Est

Financial news for OMED dated on 2017-05-04: OncoMed Doses Initial Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial

Financial news for OMED dated on 2017-04-24: OncoMed Reports Workforce Reduction by ~50%, Sees Realizing 'Significant' Cost Savings of ~\$60M Over Next 2 Years

Financial news for OMED dated on 2017-04-18: 15 Biggest Mid-Day Losers For Tuesday

Financial news for OMED dated on 2017-04-18: 7 Biggest Price Target Changes For Tuesday

Financial news for OMED dated on 2017-04-18: Benzinga's Top Upgrades, Downgrades For April 18, 2017

Financial news for OMED dated on 2017-04-18: Cantor Fitzgerald Downgrades OncoMed Pharmaceuticals to Neutral, Lowers Price Target to \$6.00

Financial news for OMED dated on 2017-04-17: Mid-Afternoon Market Update: Crude Oil Down 1%; MOCON Shares Spike Higher

Financial news for OMED dated on 2017-04-17: 15 Biggest Mid-Day Losers For Monday

Financial news for OMED dated on 2017-04-17: Mid-Day Market Update: Dow Surges Over 100 Points; Oncomed Shares Slide

Financial news for OMED dated on 2017-04-17: Piper Jaffray Downgrades OncoMed From Overweight To Neutral, Reduces Price Target From \$17 To \$5

Financial news for OMED dated on 2017-04-17: Oncomed Shares Tick ~\$0.14 Lower Over Last Few Mins as Hearing Piper Downgraded in Mid-Day Report

Financial news for OMED dated on 2017-04-17: Mid-Morning Market Update: Markets Open Higher; Ant Financial Increases Bid For Moneygram

Financial news for OMED dated on 2017-04-17: OncoMed Also Announces It Will Discontinue Enrollment In Phase 1B Clinical Trial of brontictuzumab

Financial news for OMED dated on 2017-04-17: OncoMed's Phase 2 Trial of Tarextumab Does Not Meet Endpoints

Financial news for OMED dated on 2017-04-17: OncoMed Shares Halted News Pending

Financial news for OMED dated on 2017-04-11: Benzinga's Top Upgrades, Downgrades For April 11, 2017

Financial news for OMED dated on 2017-04-11: Do Any Signs Of Life Remain In OnceMed's Demcizumab Development?

Financial news for OMED dated on 2017-04-11: BMO Capital Downgrades OncoMed Pharmaceuticals to Market Perform, Announces \$6.00 Price Target

Financial news for OMED dated on 2017-04-10: 10 Biggest Mid-Day Losers For Monday

Financial news for OMED dated on 2017-04-10: Oncomed Pharma Shares Resumed Trade, Down 47%

Financial news for OMED dated on 2017-04-10: A Peek Into The Markets: U.S. Stock Futures Mostly Up Ahead Of Labor Market Conditions Index

Financial news for OMED dated on 2017-04-10: OncoMed Pharmaceuticals to Resume Trading at 8:30 AM ET

Financial news for OMED dated on 2017-04-10: OncoMed Pharmaceuticals Reports That Bayer Terminates its Option to License Vantictumab or Ipafricept

Financial news for OMED dated on 2017-04-10: OncoMed's Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint, Will Discontinue Trial Due To Lack Of Benefit Over Standard Care

Financial news for OMED dated on 2017-04-05: Oncomed Pharma Says Phase 1B Study Of Tarextumab Shows Changes IN CTCS That Appear To Correlate With OS Outcomes, ANTI-RSPO3 With Paclitaxel Chemo Showed Synergistic Anti-Tumor Activity IN Tumors With RSPO3 Translocations

Financial news for OMED dated on 2017-04-03: UPDATE: OncoMed Says Co. Planning to Initiate Phase 1a Single-Agent Study of OMP-313M32 in 1H'17

Financial news for OMED dated on 2017-04-03: OncoMed Says Offered Data from Multiple Preclinical Studies Detailing Mechanism, Anti-Tumor Activity of Anti-TIGIT Alone, and in Combo at AACR Meeting

Financial news for OMED dated on 2017-03-08: OncoMed Pharmaceuticals Reports Q4 EPS \$(0.64) vs. \$(0.68) Est., Sales \$6.2M vs. \$8.8M Est.

Financial news for OMED dated on 2017-02-13: OncoMed Enrolls Initial Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer

Financial news for OMED dated on 2017-01-20: OncoMed Begins Enrollment of Phase 1b Clinical Trial of Brontictuzumab

Financial news for OMED dated on 2017-01-05: OncoMed Says Expecting

Financial news for OMED dated on 2017-01-04: OncoMed Initiates Enrollment of 1b Trial for Anti-DLL4

Financial news for OMED dated on 2016-12-23: 15 Stocks With The Highest Forecast Sales Growth

Financial news for OMED dated on 2016-12-19: SunTrust Robinson Humphrey Initiates Coverage On OncoMed Pharmaceuticals at Buy, Announces \$16.00 Target

Financial news for OMED dated on 2016-12-09: 10 Stocks With Lowest Close In Three Weeks

Financial news for OMED dated on 2016-12-08: Stocks Hitting 52-Week Lows

Financial news for OMED dated on 2016-12-05: OncoMed Announces Departure of Chief Medical Officer Dr. Jakob Dupont

Financial news for OMED dated on 2016-11-01: OncoMed Pharmaceuticals Reports Q3 Loss/Share \$0.77 In-Line With Estimates, Rev \$5.9M

Financial news for OMED dated on 2016-11-01: OncoMed's Phase 2 Trial Of DENALI Has Enrolled 81 Patients As Of Oct 31

Financial news for OMED dated on 2016-10-10: The ESMO Conference Proves Its Ability To Move Stocks

Financial news for OMED dated on 2016-10-10: OncoMed Shows Interim Phase 1b Data for Ipafricept and Vantictumab in Pancreatic Cancer at the ESMO 2016 Congress
GlobeNewswire - Oct 10 08:30:02.596 EDT

Financial news for OMED dated on 2016-09-22: HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, \$20 Target

Financial news for OMED dated on 2016-09-22: H.C. Wainwright Initiates Coverage on OncoMed Pharmaceuticals at Buy, Announces \$20.00 PT

Financial news for OMED dated on 2016-08-30: OncoMed Completes Enrollment of Phase 2 PINNACLE Trial

Financial news for OMED dated on 2016-08-26: BVF Reports 4.9% Passive Stake In OncoMed Pharmaceuticals in 13G

Financial news for OMED dated on 2016-08-24: Celgene Reports 8.1% Passive Stake in OncoMed Pharmaceuticals in 13G

Financial news for OMED dated on 2016-08-18: 12 Biggest Mid-Day Losers For Thursday

Financial news for OMED dated on 2016-08-18: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for OMED dated on 2016-08-18: OncoMed Price Offering of 5.5M Shares at \$10/Share

Financial news for OMED dated on 2016-08-17: OncoMed Reports Offering of Common Shares, No Specific Share Amount Disclosed

Financial news for OMED dated on 2016-08-17: OncoMed Pharmaceuticals Announces Proposed Public Offering of Common Stock

Financial news for OMED dated on 2016-08-09: OncoMed Reports Q2 EPS \$(0.91) vs. Est.

\$(0.81), Rev. \$6.6M vs. Est. \$8.09M

Financial news for OMED dated on 2016-06-05: OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at #ASCO16

Financial news for OMED dated on 2016-05-26: Mizuho Raises OncoMed Pharma's Price Target To \$16

Financial news for OMED dated on 2016-05-05: OncoMed Pharmaceuticals Reports Q1 EPS \$(0.90) Vs Est \$(0.73), Sales \$6.350M Vs Est \$8.28M

Financial news for OMED dated on 2016-04-18: Cantor Fitzgerald Initiates Coverage on OncoMed Pharmaceuticals at Buy, Announces \$16.00 PT

Financial news for OMED dated on 2016-04-12: BMO Capital Initiates Coverage on OncoMed Pharmaceuticals at Outperform, Announces \$20.00 PT

Financial news for OMED dated on 2016-03-17: OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab

Financial news for OMED dated on 2016-03-10: OncoMed Pharma Reports Q4 EPS \$(0.82) vs \$(0.50) in Same Qtr. Last Year, Sales \$6.84M vs \$8.5M YoY

Financial news for OMED dated on 2016-03-10: Earnings Scheduled For March 10, 2016

Financial news for OMED dated on 2016-02-22: UPDATE: OncoMed Says Higher Doses of Tarextumab Appear to Correlate with Improved Progression-Free, Overall Survival

Financial news for OMED dated on 2016-02-22: OncoMed Offers Updated Phase 1b Data from Tarextumab in Small Cell Lung Cancer

Financial news for OMED dated on 2016-02-08: OncoMed Offers Update on Tarextumab Phase 2 Programs: Phase 2 PINNACLE Study in Small Cell Lung Cancer Continues Following DSMB, FDA Review

Financial news for OMED dated on 2016-01-26: Does Oncomed Pharma Have Any Upside Left?

Financial news for OMED dated on 2016-01-25: Mid-Afternoon Market Update: Oncomed Pharmaceuticals Slides After Poor Trial Data; Sunedison Shares Rise

Financial news for OMED dated on 2016-01-25: Mid-Day Market Update: Crude Oil Falls 5%; Tyco Shares Surge Following Johnson Controls Merger Agreement

Financial news for OMED dated on 2016-01-25: Earlier Leerink Swann Downgraded OncoMed Pharmaceuticals to Market Perform

Financial news for OMED dated on 2016-01-25: Stocks Hitting 52-Week Lows

Financial news for OMED dated on 2016-01-25: Mid-Morning Market Update: Markets Open Lower; McDonald's Beats Q4 Estimates

Financial news for OMED dated on 2016-01-25: OncoMed Pharma Crashes 40% After Poor Trial Data

Financial news for OMED dated on 2016-01-25: Shares Of OncoMed Fall 46% From \$17.87 To \$10/Share Pre-Market

Financial news for OMED dated on 2016-01-25: UPDATE: OncoMed CEO Says Findings By DSMB Suggest Low Significant Benefit In Overall Survival In tarextumab ALPINE Pancreatic Cancer Trial

Financial news for OMED dated on 2016-01-25: UPDATE: OncoMed Says Data Safety Monitoring Board Saw Significant Worsening Of Response Rate And Progression-Free Survival In Treatment In Overall Intent-To-Treat Populaiotn

Financial news for OMED dated on 2016-01-25: OncoMed Reports Will Update Tarextumab Phase 3 ALPINE Trial via Conference Call at 8:30 a.m. EST

Financial news for OMED dated on 2016-01-22: OncoMed Reports Phase 1b Data For Demcizumab In First-Line Pancreatic Cancer

Financial news for OMED dated on 2016-01-11: OncoMed Enrolls Initial Patient in Phase 1b Anti-RSPO3 Trial

Financial news for OMED dated on 2016-01-08: OncoMed Reports Publication of Anti-RSPO Antibody Research in Cancer Research

Financial news for OMED dated on 2016-01-06: Jefferies' Best Biotech Ideas For 2016

(And Beyond)

Financial news for OMED dated on 2016-01-05: OncoMed Reports Achieved \$72.5M in Milestone Payments from Celgene; Starting '16 with \$227M in Pro-Forma Cash

Financial news for OMED dated on 2015-12-24: Benzinga's Volume Movers

Financial news for OMED dated on 2015-12-04: Wells Fargo Initiates Coverage on OncoMed Pharmaceuticals at Outperform

Financial news for OMED dated on 2015-11-07: OncoMed Presents Positive Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at SITC Conference

Financial news for OMED dated on 2015-09-16: OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference

Financial news for OMED dated on 2015-09-09: Biotech Investors Still Have Opportunity

Financial news for OMED dated on 2015-09-09: OncoMed Pharmaceuticals Reports Presentation of Tarextumab Small Cell Lung Cancer Data at the 16th World Conference on Lung Cancer

Financial news for OMED dated on 2015-08-31: OncoMed Pharmaceuticals Completes Enrollment of Phase 2 ALPINE Clinical Trial of Tarextumab in Pancreatic Cancer

Financial news for OMED dated on 2015-08-27: Notch3 Biomarker Results and Updated Data From OncoMed's Phase 1b/2 PINNACLE Clinical Trial Accepted for Presentation at the 16th World Conference on Lung Cancer

Financial news for OMED dated on 2015-08-20: 10 Biotech Stocks With Catalysts Coming Soon

Financial news for OMED dated on 2015-08-10: OncoMed Affirms FY15 Outlook for Cash Expenses, Year-End Cash, Milestone, Option Payments

Financial news for OMED dated on 2015-08-10: OncoMed Pharma Reports Q2 Sales \$4.7M, Net Loss of \$0.72/Share vs Loss of \$0.49/Share Est.

Financial news for OMED dated on 2015-07-28: OncoMed Begins Phase 1 Clinical Trial for Anti-RSPO3 Antibody

Financial news for OMED dated on 2015-06-01: OncoMed Reports Presentation of Phase 1b Trial for Tarextumab in Small Cell Lung Cancer at ASCO

Financial news for OMED dated on 2015-06-01: OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer

Financial news for OMED dated on 2015-04-22: OncoMed Begins Dosing in Randomized Phase 2 Clinical Trial of Demcizumab in Pancreatic Cancer Patients

Financial news for OMED dated on 2015-04-16: OncoMed Presents Positive Demcizumab Data from Phase 1b Clinical Trial in NSCLC Patients at European Lung Cancer Conference

Financial news for OMED dated on 2015-04-02: OncoMed, Lilly Enter Supply Agreement to Evaluate the Combination of Demcizumab and Alimta in Lung Cancer

Financial news for OMED dated on 2015-03-12: OncoMed Pharmaceuticals Reports Q4 EPS -\$0.50 vs Est -\$0.27, Sales \$8.52M Vs Est \$18.24

Financial news for OMED dated on 2015-02-04: OncoMed Reports Initiation of Phase 2 Trial Dosing of Demcizumab for Treatment of Non-Small Cell Lung Cancer

Financial news for OMED dated on 2015-02-04: OncoMed Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for Treatment of NSCLC

Financial news for OMED dated on 2015-01-29: FDA Grants Orphan Drug Designations to OncoMed's Tarextumab

Financial news for OMED dated on 2015-01-16: OncoMed Presents Final Phase 1b Safety, Efficacy and Biomarker Data for Tarextumab At Gastrointestinal Cancer Symposium

Financial news for OMED dated on 2015-01-15: OncoMed Enrolls First Biomarker-Selected Patient in Expansion Stage of Anti-Notch1 Phase 1a Trial

Financial news for OMED dated on 2015-01-09: From Amended 13G: Vertical Fund Reports 8.4% Stake In OncoMed

Financial news for OMED dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With

Robust Drug Pipelines

Financial news for OMED dated on 2014-12-01: OncoMed Begins Patient Dosing In Phase 2 Clinical Trial Of Tarextumab In Small Cell Lung Cancer

Financial news for OMED dated on 2014-11-21: OncoMed Pharma Offers Data from New Clinical, Biomarker Trial from Tarextumab, Demcizumab

Financial news for OMED dated on 2014-11-19: Oncomed Offers Data from Phase 1a Trial of OMP-52M51 in Oral Plenary Session

Financial news for OMED dated on 2014-11-03: OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent In The U.S.

Financial news for OMED dated on 2014-10-30: OncoMed to Present Clinical and Preclinical Data at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting

Financial news for OMED dated on 2014-10-07: Jefferies Initiates Coverage on OncoMed at Market Outperform, Announces \$28.00 PT

Financial news for OMED dated on 2014-09-30: Oncomed Reports Selection of First Small Molecule Product Candidate, Will Receive \$2M Milestone Payment

Financial news for OMED dated on 2014-09-28: OncoMed Announces Encouraging Safety and Anti-Tumor Activity in Demcizumab Phase 1b Clinical Trials at ESMO

Financial news for OMED dated on 2014-09-14: 3 Companies Investing In Stem Cell Research

Financial news for OMED dated on 2014-09-10: Events for the Week of Sept. 8-12

Financial news for OMED dated on 2014-09-04: FDA Removes Partial Clinical Hold On OncoMed's Ipafricept

Financial news for OMED dated on 2014-08-28: Oncomed Pharma Announces REMoval of Partial Clinical Hold for Vantictumab

Financial news for OMED dated on 2014-08-07: OncoMed Reports Q2 EPS of \$(0.53), Down 29% YOY; Revenue of \$6.01M, Up 105% YOY

Financial news for OMED dated on 2014-07-16: OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer

Financial news for OMED dated on 2014-07-02: Omnitek Announces Patents Relating to FZD-Fc Soluble Receptors

Financial news for OMED dated on 2014-06-18: Oncomed Issues Update on FZD8-Fc Phase I Trials, FDA Agreed to Voluntary Halt, Reports Partial Clinical Hold

Financial news for OMED dated on 2014-06-14: OncoMed Presents Data for Notch1 Diagnostic Assay at EHA

Financial news for OMED dated on 2014-06-13: Oncomed Announces Vantictumab Placed on Partial Clinical Hold Following Voluntary Halt by Co.

Financial news for OMED dated on 2014-06-13: Mid-Afternoon Market Update: Markets Reverse Early Loses; Oil Continues To Rise On Overseas Worry

Financial news for OMED dated on 2014-06-13: Mid-Morning Market Update: Markets Mostly Flat; Priceline To Acquire OpenTable For \$103/Share

Financial news for OMED dated on 2014-06-13: Morning Market Losers

Financial news for OMED dated on 2014-06-13: OncoMed Voluntarily Stops Enrollment For Phase 1 Vantictumab

Financial news for OMED dated on 2014-05-14: OncoMed To Present Data From Three Clinical Studies at American Society of Clinical Oncology May 31-June 1

Financial news for OMED dated on 2014-05-08: OncoMed Reports Q1 EPS of \$(0.47) vs \$(0.13) Est; Revenue of \$6.02M vs \$16.58M Est

Financial news for OMED dated on 2014-05-02: OncoMed Release Confirms Orphan Drug Designation from FDA for Demcizumab in Pancreatic Cancer

Financial news for OMED dated on 2014-05-01: Oncomed's Demcizumab for Pancreatic Cancer Has Received Orphan Drug Designation - Bloomberg

Financial news for OMED dated on 2014-04-08: OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting

Financial news for OMED dated on 2014-03-18: OncoMed Reports Q4 EPS of \$(0.15), Inline; Revenue of \$19.0M vs \$20.97M Est; Says William WAddill Leaving Co., Names Sunil Patel as CFO

Financial news for OMED dated on 2014-02-20: OncoMed Pharmaceuticals Commences Third Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Carboplatin and Paclitaxel in Ovarian Cancer

Financial news for OMED dated on 2014-02-18: OncoMed Pharma Begins Second Phase 1b Trial for OMP-54F28 with Sorafenib in Hepatocellular Cancer

Financial news for OMED dated on 2014-02-18: UPDATE: OncoMed Pharmaceuticals Initiates Second Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Sorafenib (Nexavar(R)) in Hepatocellular Cancer

Financial news for OMED dated on 2014-02-11: Benzinga's Top Initiations

Financial news for OMED dated on 2014-02-11: Mizuho Securities Initiates Coverage on OncoMed at Buy, Announces \$45.00 PT

Financial news for OMED dated on 2014-02-03: OncoMed Pharmaceuticals Granted Fourth RSPO-LGR Pathway Patent in U.S.

Financial news for OMED dated on 2014-01-17: Oncomed Pharma Say 50% of Evaluable Patients Had Partial Responses in Study of OMP-59R5, Planning Phase Trial in 2H of 2014

Financial news for OMED dated on 2013-12-17: Slideshow: The Top 10 'Highs & Dives' Of S&P 500 Stocks In 2013

Financial news for OMED dated on 2013-12-16: 13G Filing from Celgene on Oncomed Pharma Shows 5% Stake

Financial news for OMED dated on 2013-12-04: Market Wrap For November 4: Economy Is Steady, Tapering Could Be Around The Corner

Financial news for OMED dated on 2013-12-04: Mid-Day Market Update: U.S. Stocks Turn Red; OmniVision Shares Tumble On Weak Outlook

Financial news for OMED dated on 2013-12-04: UPDATE: Jefferies Reiterates on OncoMed Pharmaceuticals as CELG Collaboration Validates OMED's Platform and Pipeline

Financial news for OMED dated on 2013-12-04: Benzinga's Volume Movers

Financial news for OMED dated on 2013-12-04: Mid-Morning Market Update: Markets Edge Higher; Express Issues Downbeat Earnings Outlook

Financial news for OMED dated on 2013-12-04: OncoMed Pharma Begins Phase 1B Trial of WNT-Parthway-Target Antibody

Financial news for OMED dated on 2013-12-04: Benzinga's Top #PreMarket Gainers

Financial news for OMED dated on 2013-12-03: Market Wrap For December 3: Markets Finish In The Red For Third Straight Day

Financial news for OMED dated on 2013-12-03: Mid-Afternoon Market Update: Strong U.S. Auto Sales Numbers Unable to Buoy Market as Indexes Go Red

Financial news for OMED dated on 2013-12-03: Mid-Day Market Update: Dow Down Over 100 Points; Apple Shares Gain

Financial news for OMED dated on 2013-12-03: Shares of OncoMed Break Above \$25 Level, Now Up 100% to \$28; BMO Earlier Boosted Target from \$32 to \$43

Financial news for OMED dated on 2013-12-03: Benzinga's Volume Movers

Financial news for OMED dated on 2013-12-03: Morning Market Movers

Financial news for OMED dated on 2013-12-03: Benzinga's Top #PreMarket Gainers

Financial news for OMED dated on 2013-12-03: Oncomed Shares Rise 81% on Deal to Sell 1.47M Shares to Celgene at \$15.13/Share

Financial news for OMED dated on 2013-12-03: OncoMed Shares Resume Trade Up 77%

Financial news for OMED dated on 2013-12-03: PREVIEW: OncoMed Pharmaceuticals to Resume Trading at 8:00 AM ET

Financial news for OMED dated on 2013-12-03: Oncomed Says Will Sell 1.47M Shares at \$15.13/Share to Celgene, Expecting Gross Proceeds \$22.3M

Financial news for OMED dated on 2013-12-03: UPDATE: Celgene Receives Exclusive Option for Demcizumab

Financial news for OMED dated on 2013-12-03: Oncomed, Celgene Announce Strategic Deal Advancing Multiple

Financial news for OMED dated on 2013-12-03: OncoMed Pharma Halted News Pending

Financial news for OMED dated on 2013-11-12: OncoMed Reports Q3 EPS of \$(0.15) vs \$(0.02) Est; Revenue of \$12.90M vs \$15.77M Est

Financial news for OMED dated on 2013-11-05: Oncomed Says OMP-54F28 Program Reaches Milestone, Will Receive \$15M Payment from Bayer Pharma

Financial news for OMED dated on 2013-09-19: OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Demcizumab (Anti-DLL4) in Combination with Paclitaxel in Ovarian Cancer

Financial news for OMED dated on 2013-08-22: OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)

Financial news for OMED dated on 2013-08-12: UPDATE: Jefferies Initiates OncoMed Pharmaceuticals at Buy on Market Leader Position

Financial news for OMED dated on 2013-08-12: Leerink Swann Initiates Coverage on OncoMed at Outperform, Announces \$27.00 PT

Financial news for OMED dated on 2013-08-12: UPDATE: Piper Jaffray Initiates OncoMed Pharmaceuticals at Overweight on Emerging Cancer Antibody Play

Financial news for OMED dated on 2013-08-12: Benzinga's Top Initiations

Financial news for OMED dated on 2013-08-12: BMO Capital Initiates Coverage on OncoMed at Outperform, Announces \$32.00 PT

Financial news for OMED dated on 2013-08-12: Jefferies Initiates Coverage on OncoMed at Buy, Announces \$27.00 PT

Financial news for OMED dated on 2013-08-12: Piper Jaffray Initiates Coverage on OncoMed at Overweight, Announces \$30.00 PT

Financial news for OMED dated on 2013-07-25: Stocks Hitting 52-Week Lows

Financial news for OMED dated on 2013-07-18: OncoMed IPO Opens at \$28.12

Financial news for OMED dated on 2013-07-18: OncoMed Pharmaceuticals Scheduled for Quotation at 10:25 AM ET; Scheduled to Open at 10:40 AM ET

Financial news for OMED dated on 2013-07-18: Adam F Tweets OncoMed IPO 10x Oversubscribed, According to Source